Cargando…

P1166: BRIGATINIB IN PATIENTS WITH ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA WHO HAVE FAILED BRENTUXIMAB VEDOTIN

Detalles Bibliográficos
Autores principales:	Veleanu, Layla, Tesson, Bruno, Lamant, Laurence, Marçais, Ambroise, Bruneau, Julie, Kaltenbach, Sophie, Brouzes, Chantal, Degoutte, Charlotte, Moraly, Josquin, Villarese, Patrick, Lhermitte, Ludovic, Latiri, Mehdi, Hure, Gregoire, Chauchet, Adrien, Delette, Caroline, Grosleron, Sylvie, Toussaint, Elise, Cabrera, Quentin, Brice, Pauline, Gros, Francois-Xavier, Clavert, Aline, Oberic, Lucie, Legoff, Marielle, Cereja, Sophie, Meggetto, Fabienne, Macintyre, Elizabeth, Asnafi, Vahid, Sibon, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431189/ http://dx.doi.org/10.1097/01.HS9.0000971560.73604.5e

Ejemplares similares

De novo generation of the NPM-ALK fusion recapitulates the pleiotropic phenotypes of ALK+ ALCL pathogenesis and reveals the ROR2 receptor as target for tumor cells
por: Babin, Loélia, et al.
Publicado: (2022)

Experience of 1166 Thyroidectomy without Use of Prophylactic Antibiotic
por: Lu, Qiang, et al.
Publicado: (2014)

Brigatinib for non-small cell lung cancer
Publicado: (2020)

Investigation into the Formation of Impurities during the Optimization of Brigatinib
por: Guo, Aofeng, et al.
Publicado: (2020)

Effect of severe renal impairment on the pharmacokinetics of brigatinib
por: Gupta, Neeraj, et al.
Publicado: (2021)

Brigatinib pharmacokinetics in patients with chronic hepatic impairment
por: Hanley, Michael J., et al.
Publicado: (2023)

Endoscopic endonasal transsphenoidal surgery of 1,166 pituitary adenomas
por: Wang, Fuyu, et al.
Publicado: (2014)

Optical genome mapping refines cytogenetic diagnostics, prognostic stratification and provides new molecular insights in adult MDS/AML patients
por: Balducci, Estelle, et al.
Publicado: (2022)

Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer
por: Gupta, Neeraj, et al.
Publicado: (2020)

Targeting IRAK1 in T-Cell acute lymphoblastic leukemia
por: Dussiau, Charles, et al.
Publicado: (2015)

Simultaneous Quantification of Brigatinib and Brigatinib-Analog in Rat Plasma and Brain Homogenate by LC-MS/MS: Application to Comparative Pharmacokinetic and Brain Distribution Studies
por: Li, Bo, et al.
Publicado: (2019)

CAR T-cell detection scoping review: an essential biomarker in critical need of standardization
por: Turicek, David P, et al.
Publicado: (2023)

1166. Infection Rate in Venous–Venous Extracorporeal Membrane Oxygenation (VV-ECMO)
por: Wang, Joseph, et al.
Publicado: (2019)

1166. Evaluating the Impact of the 2016 Candidemia Guidelines on the Incidence of Ocular Complications of Candidemia
por: Hillenbrand, Molly, et al.
Publicado: (2020)

1166. Reverse Syphilis Screening and Adherence to The Congenital Syphilis Guidelines: Institutional Experience
por: Chatani, Brandon, et al.
Publicado: (2021)

The role of brigatinib in crizotinib-resistant non-small cell lung cancer
por: Mezquita, Laura, et al.
Publicado: (2018)

Repurposing Brigatinib for the Treatment of Colorectal Cancer Based on Inhibition of ER-phagy
por: Zhang, Zhe, et al.
Publicado: (2019)

Novel ALK mutation with durable response to brigatinib—a case report
por: Latif, Hira, et al.
Publicado: (2020)

Clinical Pharmacology of Brigatinib: A Next-Generation Anaplastic Lymphoma Kinase Inhibitor
por: Gupta, Neeraj, et al.
Publicado: (2023)

Test a vide des traversees dessin SI-3-76-1166-2D
por: Riboni, P, et al.
Publicado: (1977)

ALK ‐rearranged lung adenocarcinoma resistant to alectinib with cauliflower gingival metastasis responds to brigatinib
por: Song, Lianxi, et al.
Publicado: (2022)

Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study
por: Descourt, Renaud, et al.
Publicado: (2022)

AT1R A1166C variants in patients with type 2 diabetes mellitus and diabetic nephropathy
por: Moradi, Mahmoudreza, et al.
Publicado: (2015)

Association of Central Obesity with Sex Hormonebinding Globulin: A Cross-sectional Study of 1166 Chinese Men
por: Liu, Fangwei, et al.
Publicado: (2018)

Protective effect of early immunomodulatory treatment on ocular involvement in Behcet's disease: Historical cohort of 1166 patients
por: Tehrani-Banihashemi, Arash, et al.
Publicado: (2023)

Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma
por: Mitou, Géraldine, et al.
Publicado: (2015)

Low level CpG island promoter methylation predicts a poor outcome in adult T-cell acute lymphoblastic leukemia
por: Touzart, Aurore, et al.
Publicado: (2020)

Clinical Trials of Adult T-Cell Leukaemia/Lymphoma Treatment
por: Marçais, Ambroise, et al.
Publicado: (2012)

Pharmacokinetically‐guided dosing to improve the efficacy of brigatinib in non‐small cell lung cancer patients
por: Koele, Simon E., et al.
Publicado: (2021)

Association between angiotensin II receptor type 1 A1166C polymorphism and chronic kidney disease
por: Chang, Hsien-Feng, et al.
Publicado: (2018)

SG-APSIC1166: Strategies to reduce hospital-onset Clostridioides difficile infections in an acute-care hospital in Singapore
por: Foo, Shi Yun, et al.
Publicado: (2023)

Doxorubicin-induced loss of DNA topoisomerase II and DNMT1- dependent suppression of MiR-125b induces chemoresistance in ALK-positive cells
por: Congras, Annabelle, et al.
Publicado: (2018)

miR-497 suppresses cycle progression through an axis involving CDK6 in ALK-positive cells
por: Hoareau-Aveilla, Coralie, et al.
Publicado: (2019)

Alectinib and Brigatinib: New Second-Generation ALK Inhibitors for the Treatment of Non–Small Cell Lung Cancer
por: Beardslee, Tyler, et al.
Publicado: (2018)

Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy
por: Ali, Robert, et al.
Publicado: (2019)

The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers
por: Sabari, Joshua K, et al.
Publicado: (2017)

LC-ESI-MS/MS reveals the formation of reactive intermediates in brigatinib metabolism: elucidation of bioactivation pathways
por: Kadi, Adnan A., et al.
Publicado: (2018)

1166: IN-PATIENT ANTIBIOTIC EXPOSURE PROMOTES SARS-COV-2 PERSISTENCE IN THE GI TRACT IN COVID-19 ADMITTED PATIENTS
por: Sharma, Ashok, et al.
Publicado: (2022)

The Role of Angiotensin II Type 1 Receptor A1166C Polymorphism in Autosomal Dominant Polycystic Kidney Disease
por: Sasidharan, Anand, et al.
Publicado: (2023)

Arsenic trioxide (As(2)O(3)) as a maintenance therapy for adult T cell leukemia/lymphoma
por: Marçais, Ambroise, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7ro0d58fhq6k5aktpaqu379vs1